Mirum Pharmaceuticals, Inc. recently held an investor call to discuss the interim analysis results from two important studies involving the drug Volixibat. The Volixibat VANTAGE Phase 2b study focused on primary biliary cholangitis (PBC), while the Volixibat VISTAS Phase 2b study centered on primary sclerosing cholangitis (PSC).
During the call, which took place on Monday, June 17 at 8:30 a.m. ET, key findings from these studies were shared with investors and stakeholders. Those interested in accessing the call were provided with dial-in information, including a toll-free number for U.S. participants and an international number for those calling from abroad. Additionally, a webcast of the call was made available through the Events & Presentations section on Mirum’s website, with a replay option for those who missed the live event.
Mirum Pharmaceuticals, Inc. is a renowned biopharmaceutical company committed to improving treatment options for individuals affected by rare diseases, both children and adults. The company currently offers three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, has been approved for treating rare liver conditions in both pediatric and adult populations. It is indicated for cholestatic pruritus in patients with Alagille syndrome in various regions globally, as well as for cholestatic pruritus in PFIC patients. CHOLBAM is another FDA-approved medication used for specific liver disorders, while CHENODAL has received recognition from the FDA for treating patients with cerebrotendinous xanthomatosis (CTX).
Looking ahead, Mirum’s pipeline includes promising investigational treatments for severe liver diseases. Volixibat, an IBAT inhibitor, is currently undergoing evaluation in the VISTAS study for primary sclerosing cholangitis and the VANTAGE study for primary biliary cholangitis. Moreover, CHENODAL is being studied in the RESTORE Phase 3 clinical trial for patients with CTX, with positive results already reported in 2023.
For more information about Mirum Pharmaceuticals, Inc. and its ongoing efforts, individuals are encouraged to visit the company’s official website and connect on social media platforms such as Facebook, LinkedIn, Instagram, and Twitter.
In conclusion, the recent investor call held by Mirum Pharmaceuticals, Inc. provided valuable insights into the progress of their research and development activities, particularly regarding the Volixibat studies. As the company continues to focus on addressing unmet medical needs in the realm of rare diseases, stakeholders can anticipate further advancements and potential breakthroughs in the near future.
